Jesus Berdeja, MD

Articles by Jesus Berdeja, MD

Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

February 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

ByJesus Berdeja, MD

January 27th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

ByJesus Berdeja, MD

January 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.